Hui Li
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Hui Li has a total of 54 co-authors. Here are the top co-authors by number of shared publications:
- Zhenhai Zhang
Affiliated Hospital of Integrated Traditional Chinese and Western Medicine, Nanjing University of Chinese Medicine, Nanjing, China
3 shared publications - An Kang
School of Pharmacy, Nanjing University of Chinese Medicine, Nanjing, 210023, China
2 shared publications Jing Liu
Jiangsu Province Academy of Traditional Chinese Medicine, 210028 Nanjing, China
2 shared publicationsLi Cui
Affiliated Hospital of Integrated Traditional Chinese and Western Medicine, Nanjing University of Chinese Medicine, Nanjing, 210028, Jiangsu, PR China
2 shared publicationsShuting Zou
Jiangsu Province Academy of Traditional Chinese Medicine, 210028 Nanjing, China
2 shared publicationsZhentao An
Affiliated Hospital of Integrated Traditional Chinese and Western Medicine, Nanjing University of Chinese Medicine, Nanjing, 210028, Jiangsu, PR China
2 shared publications
Latest Publications
- 25 June 2026
- Published by Springer Nature in Naunyn-Schmiedeberg's Archives of Pharmacology
- Vol. 399 (12) , 1-17
Study on the therapeutic effects of the primary active ingredients in cinnamon oil for constipation-predominant irritable bowel syndrome and their regulatory effects on the 5-HT signaling pathway and gut microbiota
Cinnamon oil exhibits therapeutic potential against constipation-predominant irritable bowel syndrome (IBS-C). This study aimed to evaluate the efficacy and mechanisms of its main components—cinnamaldehyde (CAL), cinnamyl alcohol (COL), and trans-cinnamic acid (TCA)—in IBS-C. This study established an IBS-C mouse model using loperamide hydrochloride and restraint stress, and evaluated indicators such as body weight, the number of fecal pellets, fecal water content, visceral hypersensitivity, and small intestinal propulsion rate. The analysis was performed via HE staining, ELISA, Western blot, qRT-PCR, and 16S rRNA sequencing. All three components ameliorated low-grade immune cell infiltration in colonic tissue and reduced serum levels of IL-6, IL-8, and TNF-α. They also increased motilin (MTL) and acetylcholine (Ach) levels; all except trans-cinnamic acid low-dose (TCA-L) increased gastrin (Gas) levels, and all except TCA-L and trans-cinnamic acid high-dose (TCA-H) increased 5-HT levels. Cinnamaldehyde high-dose (CAL-H), cinnamyl alcohol high-dose (COL-H), and TCA-H upregulated the expression of tryptophan hydroxylase 1 (TPH1), serotonin transporter (SERT), and 5-hydroxytryptamine receptor 4 (5-HT4R) and partially modulated gut microbiota composition. CAL showed favorable effects under the present experimental conditions. The three components alleviated IBS-C symptoms partially through modulating the 5-HT signaling pathway and gut microbiota, with CAL showing the most pronounced effects under the present experimental conditions.
- 25 June 2026
- Published by Springer Nature in Naunyn-Schmiedeberg's Archives of Pharmacology
- Vol. 399 (12) , 1-17
Study on the therapeutic effects of the primary active ingredients in cinnamon oil for constipation-predominant irritable bowel syndrome and their regulatory effects on the 5-HT signaling pathway and gut microbiota
Cinnamon oil exhibits therapeutic potential against constipation-predominant irritable bowel syndrome (IBS-C). This study aimed to evaluate the efficacy and mechanisms of its main components—cinnamaldehyde (CAL), cinnamyl alcohol (COL), and trans-cinnamic acid (TCA)—in IBS-C. This study established an IBS-C mouse model using loperamide hydrochloride and restraint stress, and evaluated indicators such as body weight, the number of fecal pellets, fecal water content, visceral hypersensitivity, and small intestinal propulsion rate. The analysis was performed via HE staining, ELISA, Western blot, qRT-PCR, and 16S rRNA sequencing. All three components ameliorated low-grade immune cell infiltration in colonic tissue and reduced serum levels of IL-6, IL-8, and TNF-α. They also increased motilin (MTL) and acetylcholine (Ach) levels; all except trans-cinnamic acid low-dose (TCA-L) increased gastrin (Gas) levels, and all except TCA-L and trans-cinnamic acid high-dose (TCA-H) increased 5-HT levels. Cinnamaldehyde high-dose (CAL-H), cinnamyl alcohol high-dose (COL-H), and TCA-H upregulated the expression of tryptophan hydroxylase 1 (TPH1), serotonin transporter (SERT), and 5-hydroxytryptamine receptor 4 (5-HT4R) and partially modulated gut microbiota composition. CAL showed favorable effects under the present experimental conditions. The three components alleviated IBS-C symptoms partially through modulating the 5-HT signaling pathway and gut microbiota, with CAL showing the most pronounced effects under the present experimental conditions.
- Open Access
- 25 December 2025
- Published by EWA Publishing in Journal of Clinical Technology and Theory
- Vol. 4 (1) , 11-20
Research progress on risk factors for recurrence of colorectal adenomas after endoscopic resection and postoperative prevention and treatment
Colorectal Adenoma (CRA) is the main precancerous lesion of Colorectal Cancer (CRC). Its early detection and intervention are of great significance for reducing the incidence of CRC. Currently, endoscopic treatment is the most commonly used and effective method. However, there is still a certain risk of recurrence after adenoma resection, and some may progress to high-grade intraepithelial neoplasia or even CRC. Studies have shown that the recurrence mechanism of CRA is a complex process involving multiple factors, which is closely related to individual patient factors, adenoma characteristics, and factors related to endoscopic operations. Research on the prevention of adenoma recurrence is relatively scarce. In the field of Western medicine, Western drugs are the mainstay, while Traditional Chinese Medicine (TCM) prevents adenoma recurrence through syndrome differentiation using internal and external treatments, but both lack clear mechanism research and support from high-quality evidence-based medical evidence. This article investigates the research progress on the recurrence of CRA at home and abroad in recent years, evaluates some existing recurrence prediction models and monitoring strategies, and finally reviews the existing prevention methods of integrated traditional Chinese and Western medicine, aiming to provide reference for clinical practice, optimize postoperative monitoring strategies and individualized prevention and treatment plans, and ultimately achieve the goal of reducing the risk of CRC.
- 25 December 2025
- Published by EWA Publishing in Journal of Clinical Technology and Theory
- Vol. 4 (1) , 11-20
Open AccessResearch progress on risk factors for recurrence of colorectal adenomas after endoscopic resection and postoperative prevention and treatment
Colorectal Adenoma (CRA) is the main precancerous lesion of Colorectal Cancer (CRC). Its early detection and intervention are of great significance for reducing the incidence of CRC. Currently, endoscopic treatment is the most commonly used and effective method. However, there is still a certain risk of recurrence after adenoma resection, and some may progress to high-grade intraepithelial neoplasia or even CRC. Studies have shown that the recurrence mechanism of CRA is a complex process involving multiple factors, which is closely related to individual patient factors, adenoma characteristics, and factors related to endoscopic operations. Research on the prevention of adenoma recurrence is relatively scarce. In the field of Western medicine, Western drugs are the mainstay, while Traditional Chinese Medicine (TCM) prevents adenoma recurrence through syndrome differentiation using internal and external treatments, but both lack clear mechanism research and support from high-quality evidence-based medical evidence. This article investigates the research progress on the recurrence of CRA at home and abroad in recent years, evaluates some existing recurrence prediction models and monitoring strategies, and finally reviews the existing prevention methods of integrated traditional Chinese and Western medicine, aiming to provide reference for clinical practice, optimize postoperative monitoring strategies and individualized prevention and treatment plans, and ultimately achieve the goal of reducing the risk of CRC.
- Open Access
- 23 September 2025
- Published by EWA Publishing in Journal of Clinical Technology and Theory
- Vol. 3 (3) , 15-18
Research progress on the treatment of peptic ulcers with cuttlefish bone
Peptic ulcer is a common disease of the digestive system, referring to a defect in the gastrointestinal mucosa that usually extends beyond the mucosal muscular layer. Globally, both its incidence and recurrence rates are relatively high, severely affecting patients quality of life. The typical symptom of peptic ulcer is upper abdominal pain, which belongs to the category of stomach pain in traditional Chinese medicine. Long-term use of therapeutic drugs such as proton pump inhibitors and H receptor antagonists brings drawbacks. The emergence of Helicobacter pylori resistant strains and the increasing elderly population, together with more frequent use of anti-inflammatory, analgesic, and antithrombotic drugs, make the prevention and treatment of PU more difficult. At present, traditional Chinese medicine has definite efficacy in treating gastrointestinal ulcers. Among them, cuttlefish bone has a clear therapeutic effect on peptic ulcers, with the functions of astringing to stop bleeding, consolidating essence to stop leucorrhea, neutralizing gastric acid to relieve pain, and absorbing dampness to heal sores. This paper analyzes the reliability of cuttlefish bone in treating peptic ulcers from the perspectives of clinical application, clinical trials, and laboratory research, aiming to provide a reference for the clinical use of medications in peptic ulcer treatment.
- 23 September 2025
- Published by EWA Publishing in Journal of Clinical Technology and Theory
- Vol. 3 (3) , 15-18
Open AccessResearch progress on the treatment of peptic ulcers with cuttlefish bone
Peptic ulcer is a common disease of the digestive system, referring to a defect in the gastrointestinal mucosa that usually extends beyond the mucosal muscular layer. Globally, both its incidence and recurrence rates are relatively high, severely affecting patients quality of life. The typical symptom of peptic ulcer is upper abdominal pain, which belongs to the category of stomach pain in traditional Chinese medicine. Long-term use of therapeutic drugs such as proton pump inhibitors and H receptor antagonists brings drawbacks. The emergence of Helicobacter pylori resistant strains and the increasing elderly population, together with more frequent use of anti-inflammatory, analgesic, and antithrombotic drugs, make the prevention and treatment of PU more difficult. At present, traditional Chinese medicine has definite efficacy in treating gastrointestinal ulcers. Among them, cuttlefish bone has a clear therapeutic effect on peptic ulcers, with the functions of astringing to stop bleeding, consolidating essence to stop leucorrhea, neutralizing gastric acid to relieve pain, and absorbing dampness to heal sores. This paper analyzes the reliability of cuttlefish bone in treating peptic ulcers from the perspectives of clinical application, clinical trials, and laboratory research, aiming to provide a reference for the clinical use of medications in peptic ulcer treatment.
- Open Access
- 16 June 2025
- Published by Springer Nature in Chinese Medicine
- Vol. 20 (1) , 1-18
Quercetagetin alleviates liver fibrosis in non-alcoholic fatty liver disease by promoting ferroptosis of hepatic stellate cells through GPX4 ubiquitination
Background: Lang Qing A Ta (Huagan Tongluo Fang, HGTLF) is a Tibetan medicine with significant anti-liver fibrosis effects and good efficacy in the treatment of liver diseases, including non-alcoholic fatty liver disease (NAFLD). Quercetagetin (QG) has been identified as an active ingredient of HGTLF that is absorbed into the blood. This study aims to investigate the role of QG in the anti-liver fibrosis effect of HGTLF in NAFLD. Methods: CCl4 injection-induced liver fibrosis and high-fat, high-cholesterol diet-induced non-alcoholic steatohepatitis (NASH) mouse models were established. Transforming growth factor-β1 (TGF-β1)-induced hepatic stellate cells (HSCs) were used as in vitro models. The effect of QG on the stability and degradation pathway of glu-tathione peroxidase 4 (GPX4) protein was investigated. Results: QG improved liver function and hyperlipidemia in CCl4-injected mice and NASH mice, and alleviated hepatic lipid deposition and hepatic fibrosis. TGF-β1 treatment promoted the expression of α-smooth muscle actin and fibrosis-related genes, while QG reversed this phenomenon and inhibited HSC activation. QG increased the intracellular labile iron pool and lipid reactive oxygen species in HSCs. Treatment with the ferroptosis inhibitor ferrostatin-1 reversed the inhibitory effect of QG on TGF-β1-induced HSC activation. QG reduced GPX4 protein stability and regulated GPX4 K167 ubiquitination via the membrane-associated ring-CH-type finger 8 (MARCHF8)-mediated ubiquitin–proteasome pathway. Interference with MARCHF8 attenuated the effect of QG and promoted HSC activation induced by TGF-β1. Conclusion: QG, the active ingredient of HGTLF, can induce ferroptosis of HSCs by targeting the degradation of GPX4 through ubiquitination and inhibit HSC activation, thereby alleviating liver fibrosis in NAFLD.
- 16 June 2025
- Published by Springer Nature in Chinese Medicine
- Vol. 20 (1) , 1-18
Open AccessQuercetagetin alleviates liver fibrosis in non-alcoholic fatty liver disease by promoting ferroptosis of hepatic stellate cells through GPX4 ubiquitination
Background: Lang Qing A Ta (Huagan Tongluo Fang, HGTLF) is a Tibetan medicine with significant anti-liver fibrosis effects and good efficacy in the treatment of liver diseases, including non-alcoholic fatty liver disease (NAFLD). Quercetagetin (QG) has been identified as an active ingredient of HGTLF that is absorbed into the blood. This study aims to investigate the role of QG in the anti-liver fibrosis effect of HGTLF in NAFLD. Methods: CCl4 injection-induced liver fibrosis and high-fat, high-cholesterol diet-induced non-alcoholic steatohepatitis (NASH) mouse models were established. Transforming growth factor-β1 (TGF-β1)-induced hepatic stellate cells (HSCs) were used as in vitro models. The effect of QG on the stability and degradation pathway of glu-tathione peroxidase 4 (GPX4) protein was investigated. Results: QG improved liver function and hyperlipidemia in CCl4-injected mice and NASH mice, and alleviated hepatic lipid deposition and hepatic fibrosis. TGF-β1 treatment promoted the expression of α-smooth muscle actin and fibrosis-related genes, while QG reversed this phenomenon and inhibited HSC activation. QG increased the intracellular labile iron pool and lipid reactive oxygen species in HSCs. Treatment with the ferroptosis inhibitor ferrostatin-1 reversed the inhibitory effect of QG on TGF-β1-induced HSC activation. QG reduced GPX4 protein stability and regulated GPX4 K167 ubiquitination via the membrane-associated ring-CH-type finger 8 (MARCHF8)-mediated ubiquitin–proteasome pathway. Interference with MARCHF8 attenuated the effect of QG and promoted HSC activation induced by TGF-β1. Conclusion: QG, the active ingredient of HGTLF, can induce ferroptosis of HSCs by targeting the degradation of GPX4 through ubiquitination and inhibit HSC activation, thereby alleviating liver fibrosis in NAFLD.
- 20 December 2023
- Published by Elsevier in International Immunopharmacology
- Vol. 127, 111404
Potential effects of sodium hyaluronate on constipation-predominant irritable bowel syndrome
- 20 December 2023
- Published by Elsevier in International Immunopharmacology
- Vol. 127, 111404
Potential effects of sodium hyaluronate on constipation-predominant irritable bowel syndrome
- Open Access
- 28 October 2023
- Published by Korean Society for Microbiology and Biotechnology in Journal of Microbiology and Biotechnology
- Vol. 34 (2) , 367-378
Fenchone Ameliorates Constipation-Predominant Irritable Bowel Syndrome via Modulation of SCF/c-Kit Pathway and Gut Microbiota
Li Cui, Bin Zhang, Shuting Zou, Jing Liu, Pingrong Wang, Hui Li, and Zhenhai Zhang. J. Microbiol. Biotechnol. 2024;34:367-78. https://doi.org/10.4014/jmb.2308.08011
- 28 October 2023
- Published by Korean Society for Microbiology and Biotechnology in Journal of Microbiology and Biotechnology
- Vol. 34 (2) , 367-378
Open AccessFenchone Ameliorates Constipation-Predominant Irritable Bowel Syndrome via Modulation of SCF/c-Kit Pathway and Gut Microbiota
Li Cui, Bin Zhang, Shuting Zou, Jing Liu, Pingrong Wang, Hui Li, and Zhenhai Zhang. J. Microbiol. Biotechnol. 2024;34:367-78. https://doi.org/10.4014/jmb.2308.08011
- Open Access
- 1 January 2021
- Published by Taylor & Francis in Bioengineered
- Vol. 12 (1) , 4150-4158
Long non-coding RNA SNHG5 regulates ulcerative colitis via microRNA-375 / Janus kinase-2 axis
Ulcerative colitis (UC) is an intestinal inflammatory disorder. Long non-coding RNAs (lncRNAs) are collectively involved in UC. This study is designed to explore the roles of lncRNA (small nucleolar RNA host gene 5) SNHG5 in UC. Gene or microRNA (miRNA) expression was detected using RT-qPCR and western blot, respectively. Cellular functions were analyzed by cell counting kit 8 (CCK8), 5-ethynyl-2′-deoxyuridine (EdU) assay, flow cytometry, and the terminal deoxyribonucleotidyl transferase (TDT)‐mediated dUTP‐digoxigenin nick end labeling (TUNEL) assays. Lactate dehydrogenase (LDH) content was determined by a cell cytotoxicity assay. The interactions between miR-375 and SNHG5 or Janus kinase-2 (JAK2) were verified by a luciferase reporter assay. SNHG5 was up-regulated in intestinal mucosa tissues of UC patients as well as tumor necrosis factor alpha-treated (TNF-α-treated) young adult mouse colon (YAMC) cells. Down-regulated SNHG5 promoted cell proliferation and inhibited apoptosis of YAMC cells. miR-375 was verified to be a target of SNHG5 and was suppressed by TNF-α treatment in YAMC cells. Over-expression of miR-375 restored YAMC cellular functions. Additionally, miR-375 targeted JAK2, which was up-regulated by TNF-α treated YAMC cells. Up-regulation of JAK2 induced the dysfunction of YAMC cells. Knockdown of SNHG5 promoted the proliferation and suppressed the apoptosis of YAMC cells via regulating miR-375/JAK2 axis. Therefore, knockdown of SNHG5 may be a promising therapy for UC. Graphical Abstract
- 1 January 2021
- Published by Taylor & Francis in Bioengineered
- Vol. 12 (1) , 4150-4158
Open AccessLong non-coding RNA SNHG5 regulates ulcerative colitis via microRNA-375 / Janus kinase-2 axis
Ulcerative colitis (UC) is an intestinal inflammatory disorder. Long non-coding RNAs (lncRNAs) are collectively involved in UC. This study is designed to explore the roles of lncRNA (small nucleolar RNA host gene 5) SNHG5 in UC. Gene or microRNA (miRNA) expression was detected using RT-qPCR and western blot, respectively. Cellular functions were analyzed by cell counting kit 8 (CCK8), 5-ethynyl-2′-deoxyuridine (EdU) assay, flow cytometry, and the terminal deoxyribonucleotidyl transferase (TDT)‐mediated dUTP‐digoxigenin nick end labeling (TUNEL) assays. Lactate dehydrogenase (LDH) content was determined by a cell cytotoxicity assay. The interactions between miR-375 and SNHG5 or Janus kinase-2 (JAK2) were verified by a luciferase reporter assay. SNHG5 was up-regulated in intestinal mucosa tissues of UC patients as well as tumor necrosis factor alpha-treated (TNF-α-treated) young adult mouse colon (YAMC) cells. Down-regulated SNHG5 promoted cell proliferation and inhibited apoptosis of YAMC cells. miR-375 was verified to be a target of SNHG5 and was suppressed by TNF-α treatment in YAMC cells. Over-expression of miR-375 restored YAMC cellular functions. Additionally, miR-375 targeted JAK2, which was up-regulated by TNF-α treated YAMC cells. Up-regulation of JAK2 induced the dysfunction of YAMC cells. Knockdown of SNHG5 promoted the proliferation and suppressed the apoptosis of YAMC cells via regulating miR-375/JAK2 axis. Therefore, knockdown of SNHG5 may be a promising therapy for UC. Graphical Abstract